Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism

Sinisa Urban, Severin Urban, Karl P. Fischer, D. Lorne Tyrrell

Research output: Contribution to journalArticle

Abstract

Effective antiviral agents are thought to inhibit hepatitis B virus (HBV) DNA synthesis iirreversibly by chain termination because reverse transcriptases (RT) lack an exonucleolytic activity that can remove incorporated nucleotides. However, since the parameters governing this inhibition are poorly defined, fully delineating the catalytic mechanism of the HBV-RT promises to facilitate the development of antiviral drugs for treating chronic HBV infection. To this end, pyrophosphorolysis and pyrophosphate exchange, two nonhydrolytic RT activities that result in the removal of newly incorporated nucleotides, were characterized by using endogenous avian HBV replication complexes assembled in vivo. Although these activities are presumed to be physiologically irrelevant for every polymerase examined, the efficiency with which they are catalyzed by the avian HBV-RT strongly suggests that it is the first known polymerase to catalyze these reactions under replicative conditions. The ability to remove newly incorporated nucleotides during replication has important biological and clinical implications: these activities may serve a primer-unblocking function in vivo. Analysis of pyrophosphorolysis on chain-terminated DNA revealed that the potent anti-HBV drug β-L-(-)-2′,3′-dideoxy-3′thiacytidine (3TC) was difficult to remove by pyrophosphorolysis, in contrast to ineffective chain terminators such as ddC. This disparity may account for the strong antiviral efficacy of 3TC versus that of ddC. The HBV-RT pyrophosphorolytic activity may therefore be a novel determinant of antiviral drug efficacy, and could serve as a target for future antiviral drug therapy. The strong inhibitory effect of cytoplasmic pyrophosphate concentrations on viral DNA synthesis may also partly account for the apparent slow rate of HBV genome replication.

Original languageEnglish (US)
Pages (from-to)4984-4989
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume98
Issue number9
DOIs
StatePublished - Apr 24 2001
Externally publishedYes

Fingerprint

Hepatitis B virus
RNA-Directed DNA Polymerase
Antiviral Agents
Lamivudine
Nucleotides
Virus Replication
DNA
Viral DNA
Chronic Hepatitis B
Virus Diseases
Genome
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Antiviral inhibition
  • Core particles
  • Lamivudine/3TC
  • Proofreading

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. / Urban, Sinisa; Urban, Severin; Fischer, Karl P.; Tyrrell, D. Lorne.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 9, 24.04.2001, p. 4984-4989.

Research output: Contribution to journalArticle

@article{4e6eb9f310cd4fe6ba2e63c188e5a2bf,
title = "Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism",
abstract = "Effective antiviral agents are thought to inhibit hepatitis B virus (HBV) DNA synthesis iirreversibly by chain termination because reverse transcriptases (RT) lack an exonucleolytic activity that can remove incorporated nucleotides. However, since the parameters governing this inhibition are poorly defined, fully delineating the catalytic mechanism of the HBV-RT promises to facilitate the development of antiviral drugs for treating chronic HBV infection. To this end, pyrophosphorolysis and pyrophosphate exchange, two nonhydrolytic RT activities that result in the removal of newly incorporated nucleotides, were characterized by using endogenous avian HBV replication complexes assembled in vivo. Although these activities are presumed to be physiologically irrelevant for every polymerase examined, the efficiency with which they are catalyzed by the avian HBV-RT strongly suggests that it is the first known polymerase to catalyze these reactions under replicative conditions. The ability to remove newly incorporated nucleotides during replication has important biological and clinical implications: these activities may serve a primer-unblocking function in vivo. Analysis of pyrophosphorolysis on chain-terminated DNA revealed that the potent anti-HBV drug β-L-(-)-2′,3′-dideoxy-3′thiacytidine (3TC) was difficult to remove by pyrophosphorolysis, in contrast to ineffective chain terminators such as ddC. This disparity may account for the strong antiviral efficacy of 3TC versus that of ddC. The HBV-RT pyrophosphorolytic activity may therefore be a novel determinant of antiviral drug efficacy, and could serve as a target for future antiviral drug therapy. The strong inhibitory effect of cytoplasmic pyrophosphate concentrations on viral DNA synthesis may also partly account for the apparent slow rate of HBV genome replication.",
keywords = "Antiviral inhibition, Core particles, Lamivudine/3TC, Proofreading",
author = "Sinisa Urban and Severin Urban and Fischer, {Karl P.} and Tyrrell, {D. Lorne}",
year = "2001",
month = "4",
day = "24",
doi = "10.1073/pnas.091324398",
language = "English (US)",
volume = "98",
pages = "4984--4989",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism

AU - Urban, Sinisa

AU - Urban, Severin

AU - Fischer, Karl P.

AU - Tyrrell, D. Lorne

PY - 2001/4/24

Y1 - 2001/4/24

N2 - Effective antiviral agents are thought to inhibit hepatitis B virus (HBV) DNA synthesis iirreversibly by chain termination because reverse transcriptases (RT) lack an exonucleolytic activity that can remove incorporated nucleotides. However, since the parameters governing this inhibition are poorly defined, fully delineating the catalytic mechanism of the HBV-RT promises to facilitate the development of antiviral drugs for treating chronic HBV infection. To this end, pyrophosphorolysis and pyrophosphate exchange, two nonhydrolytic RT activities that result in the removal of newly incorporated nucleotides, were characterized by using endogenous avian HBV replication complexes assembled in vivo. Although these activities are presumed to be physiologically irrelevant for every polymerase examined, the efficiency with which they are catalyzed by the avian HBV-RT strongly suggests that it is the first known polymerase to catalyze these reactions under replicative conditions. The ability to remove newly incorporated nucleotides during replication has important biological and clinical implications: these activities may serve a primer-unblocking function in vivo. Analysis of pyrophosphorolysis on chain-terminated DNA revealed that the potent anti-HBV drug β-L-(-)-2′,3′-dideoxy-3′thiacytidine (3TC) was difficult to remove by pyrophosphorolysis, in contrast to ineffective chain terminators such as ddC. This disparity may account for the strong antiviral efficacy of 3TC versus that of ddC. The HBV-RT pyrophosphorolytic activity may therefore be a novel determinant of antiviral drug efficacy, and could serve as a target for future antiviral drug therapy. The strong inhibitory effect of cytoplasmic pyrophosphate concentrations on viral DNA synthesis may also partly account for the apparent slow rate of HBV genome replication.

AB - Effective antiviral agents are thought to inhibit hepatitis B virus (HBV) DNA synthesis iirreversibly by chain termination because reverse transcriptases (RT) lack an exonucleolytic activity that can remove incorporated nucleotides. However, since the parameters governing this inhibition are poorly defined, fully delineating the catalytic mechanism of the HBV-RT promises to facilitate the development of antiviral drugs for treating chronic HBV infection. To this end, pyrophosphorolysis and pyrophosphate exchange, two nonhydrolytic RT activities that result in the removal of newly incorporated nucleotides, were characterized by using endogenous avian HBV replication complexes assembled in vivo. Although these activities are presumed to be physiologically irrelevant for every polymerase examined, the efficiency with which they are catalyzed by the avian HBV-RT strongly suggests that it is the first known polymerase to catalyze these reactions under replicative conditions. The ability to remove newly incorporated nucleotides during replication has important biological and clinical implications: these activities may serve a primer-unblocking function in vivo. Analysis of pyrophosphorolysis on chain-terminated DNA revealed that the potent anti-HBV drug β-L-(-)-2′,3′-dideoxy-3′thiacytidine (3TC) was difficult to remove by pyrophosphorolysis, in contrast to ineffective chain terminators such as ddC. This disparity may account for the strong antiviral efficacy of 3TC versus that of ddC. The HBV-RT pyrophosphorolytic activity may therefore be a novel determinant of antiviral drug efficacy, and could serve as a target for future antiviral drug therapy. The strong inhibitory effect of cytoplasmic pyrophosphate concentrations on viral DNA synthesis may also partly account for the apparent slow rate of HBV genome replication.

KW - Antiviral inhibition

KW - Core particles

KW - Lamivudine/3TC

KW - Proofreading

UR - http://www.scopus.com/inward/record.url?scp=0035942275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035942275&partnerID=8YFLogxK

U2 - 10.1073/pnas.091324398

DO - 10.1073/pnas.091324398

M3 - Article

C2 - 11320247

AN - SCOPUS:0035942275

VL - 98

SP - 4984

EP - 4989

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -